In Merck’s case, worries over rising competition from so-called ‘biosimilar’ generic products, which approximate the biological chemical structure of branded medicines, is behind much of the ...

Four blue-chip stocks are trading near their 52-week lows and offering investors incredible entry points and huge dividends.

In JAMA, the FDA's Makary and Prasad said they will focus on modernizing review processes and lowering drug costs but don't outright mention precision medicine.

Pfizer’s PFE stock has declined 10.7% so far this year compared with a decrease of 7.7% for the industry. The stock has also ...

Indian pharma grapples headwinds of US pricing reform & Europe’s HTA-driven cost-effectiveness: Akash Kedia: Nandita Vijayasimha, Bengaluru Monday, June 9, 2025, 08:00 Hrs [IST] ...

Fintel reports that on June 6, 2025, Goldman Sachs initiated coverage of Viatris (NasdaqGS:VTRS) with a Neutral ...

A long-acting medicine developed by Novo Nordisk has been recommended as a treatment option for young people with growth ...

Going forward, Celltrion is expected to continue its current strategy, aiming to have a total of 23 biosimilar products by 2030, covering therapeutic areas such as immunology and oncology. Leveraging ...

The enzyme replacement therapy market has gained significant momentum over recent years, driven by rising awareness of rare diseases and growing access to modern healthcare services. Enzyme ...

Introduction The global market for wearable injectors is swiftly growing, propelled by the rising need for self-administration of biologics and ...

Meanwhile, BioNTech itself bought into the category with its takeover of BNT327's developer Biotheus unit last year for what ...

The global biosimilars market growth is driven by increasing number of biosimilar approvals and rising number of biologics going off-patent.A biosimilar is a biological product that is similar to a ...